REGN Regeneron Pharmaceuticals

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • Lease financing $720M matures March 2027, full payment due unless extended with lender consent
• • Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio
• • Liabilities for unrecognized tax benefits $1.578B as of December 31, 2025, with high uncertainty in settlement timing
• • Ongoing R&D and commercialization costs depend on trial outcomes, regulatory approvals, and market potential
• • Contingent payments from collaboration agreements include milestone and royalty payments with unpredictable timing

Management Discussion & Analysis

• • No revenue or profitability figures provided in the excerpt
• • No segment performance details disclosed
• • Investment portfolio equity securities decreased to $515.8M (Dec 31, 2025) from $1.307B (Dec 31, 2024)
• • Foreign exchange risk growing due to international sales and operations; foreign currency hedging strategies considered
• • No cash flow, capital allocation, or forward-looking guidance included

Business Overview

• • Core business model: Development, manufacturing, and commercialization of innovative biologic drugs and drug-delivery devices with regulatory approval focus
• • New emphasis on expanding internal manufacturing capacity and establishing fill/finish capabilities amid production constraints and pandemic-related impacts
• • Strategic reliance increased on collaborators and contract manufacturers for bulk production and complex device supply chain management
• • Manufacturing capacity limited to facilities in Rensselaer, NY and Limerick, Ireland; investing in expansion and new fill/finish facility undergoing process validation
• • Noteworthy risk: Loss of U.S. market exclusivity for EYLEA as biosimilars launched May 2024, impacting patent protection and revenue outlook

What are the latest REGN SEC filings in 2026?

Regeneron Pharmaceuticals (REGN) has filed a 10-K annual report on February 4, 2026, a 10-Q quarterly report on April 29, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did REGN file its most recent 10-K annual report?

Regeneron Pharmaceuticals (REGN) filed its most recent 10-K annual report on February 4, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view REGN 10-Q quarterly reports?

Regeneron Pharmaceuticals (REGN)'s most recent 10-Q quarterly report was filed on April 29, 2026. SignalX displays every REGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has REGN filed recently?

Regeneron Pharmaceuticals (REGN)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find REGN insider trading activity (Form 4)?

SignalX aggregates every REGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does REGN file with the SEC?

Regeneron Pharmaceuticals (REGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new REGN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Regeneron Pharmaceuticals (REGN).

What is REGN's SEC CIK number?

Regeneron Pharmaceuticals (REGN)'s SEC CIK (Central Index Key) number is 872589. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 872589 to look up all REGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find REGN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Regeneron Pharmaceuticals (REGN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.